170 related articles for article (PubMed ID: 37461214)
1. Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation.
Benz AP; Hijazi Z; Lindbäck J; Connolly SJ; Eikelboom JW; Kastner P; Ziegler A; Alexander JH; Granger CB; Lopes RD; Oldgren J; Siegbahn A; Wallentin L
Europace; 2023 Jul; 25(7):. PubMed ID: 37461214
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
3. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation.
Hijazi Z; Benz AP; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Granger CB; Kastner P; Lopes RD; Ziegler A; Oldgren J; Siegbahn A; Wallentin L
Eur Heart J; 2023 Jan; 44(3):208-218. PubMed ID: 36380569
[TBL] [Abstract][Full Text] [Related]
5. Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.
Hofer F; Pailer U; Sulzgruber P; Gerges C; Winter MP; Giugliano RP; Gottsauner-Wolf M; Hülsmann M; Kazem N; Koller L; Schönbauer R; Niessner A; Hengstenberg C; Zelniker TA
ESC Heart Fail; 2022 Aug; 9(4):2367-2377. PubMed ID: 35593128
[TBL] [Abstract][Full Text] [Related]
6. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serum N-Terminal Pro-Brain Natriuretic Peptide Level over Heart Failure for Stroke Events and Deaths in Patients with Atrial Fibrillation.
Kuronuma K; Okumura Y; Morikawa T; Yokoyama K; Matsumoto N; Tachibana E; Oiwa K; Matsumoto M; Kojima T; Haruta H; Nomoto K; Sonoda K; Arima K; Kogawa R; Takahashi F; Kotani T; Ohkubo K; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Int Heart J; 2020 May; 61(3):492-502. PubMed ID: 32418966
[TBL] [Abstract][Full Text] [Related]
10. B-type natriuretic peptide over N-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke.
Palà E; Pagola J; Juega J; Francisco-Pascual J; Bustamante A; Penalba A; Comas I; Rodriguez M; De Lera Alfonso M; Arenillas JF; de Torres R; Pérez-Sánchez S; Cabezas JA; Moniche F; González-Alujas T; Molina CA; Montaner J
Eur J Neurol; 2021 Feb; 28(2):540-547. PubMed ID: 33043545
[TBL] [Abstract][Full Text] [Related]
11. Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death.
Brady PF; Chua W; Nehaj F; Connolly DL; Khashaba A; Purmah YJV; Ul-Qamar MJ; Thomas MR; Varma C; Schnabel RB; Zeller T; Fabritz L; Kirchhof PF
J Am Heart Assoc; 2022 Feb; 11(4):e022833. PubMed ID: 35112889
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
13. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.
Werhahn SM; Becker C; Mende M; Haarmann H; Nolte K; Laufs U; Zeynalova S; Löffler M; Dagres N; Husser D; Dörr M; Gross S; Felix SB; Petersmann A; Herrmann-Lingen C; Binder L; Scherer M; Hasenfuß G; Pieske B; Edelmann F; Wachter R
ESC Heart Fail; 2022 Feb; 9(1):100-109. PubMed ID: 34850596
[TBL] [Abstract][Full Text] [Related]
14. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
Xing LY; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Frikke-Schmidt R; Olesen MS; Brandes A; Køber L; Haugan KJ; Svendsen JH
Circulation; 2023 Jun; 147(24):1788-1797. PubMed ID: 37061802
[TBL] [Abstract][Full Text] [Related]
15. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
[TBL] [Abstract][Full Text] [Related]
16. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
17. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
18. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Oyama K; Giugliano RP; Berg DD; Ruff CT; Jarolim P; Tang M; Murphy SA; Lanz HJ; Grosso MA; Antman EM; Braunwald E; Morrow DA
Eur Heart J; 2021 May; 42(17):1698-1706. PubMed ID: 33760027
[TBL] [Abstract][Full Text] [Related]
19. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study.
Jia X; Buckley L; Sun C; Al Rifai M; Yu B; Nambi V; Virani SS; Selvin E; Matsushita K; Hoogeveen RC; Coresh J; Shah AM; Ballantyne CM
Eur J Prev Cardiol; 2023 Nov; 30(16):1731-1740. PubMed ID: 37306504
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
